Acer Therapeutics Inc. is a pharmaceutical company dedicated to acquiring, developing, and commercializing treatments for severe rare and life-threatening conditions. Its clinical-stage pipeline features four key candidates: EDSIVO, for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a sodium phenylbutyrate formulation addressing inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant), designed to manage induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy showing promise against various infectious diseases, including COVID-19. The company also collaborates with the National Center for Advancing Translational Sciences (NCATS) on developing emetine hydrochloride for COVID-19 and holds worldwide licensing rights for osanetant, a selective NK3 receptor antagonist, through an agreement with Sanofi. Established in 1991, Acer Therapeutics Inc. is headquartered in Newton, Massachusetts.